Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 174.14 Billion KRW | -0.84% |
| 2022 | 175.62 Billion KRW | 7.49% |
| 2021 | 163.37 Billion KRW | 10.68% |
| 2020 | 147.6 Billion KRW | 0.92% |
| 2019 | 146.26 Billion KRW | 6.32% |
| 2018 | 137.57 Billion KRW | 23.11% |
| 2017 | 111.74 Billion KRW | 11.46% |
| 2016 | 100.25 Billion KRW | 46.79% |
| 2015 | 68.29 Billion KRW | -21.5% |
| 2014 | 87 Billion KRW | 55.57% |
| 2013 | 55.92 Billion KRW | 4.34% |
| 2012 | 53.6 Billion KRW | -0.82% |
| 2011 | 54.04 Billion KRW | 2.8% |
| 2010 | 52.57 Billion KRW | 0.48% |
| 2009 | 52.32 Billion KRW | 6.08% |
| 2008 | 49.32 Billion KRW | 6.05% |
| 2007 | 46.5 Billion KRW | -1.21% |
| 2006 | 47.08 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 41.91 Billion KRW | 6.86% |
| 2024 Q1 | 39.22 Billion KRW | -12.96% |
| 2023 Q4 | 45.06 Billion KRW | 200.65% |
| 2023 Q1 | 37.73 Billion KRW | -18.96% |
| 2023 Q3 | -44.76 Billion KRW | 5.68% |
| 2023 Q2 | -47.46 Billion KRW | -225.79% |
| 2023 FY | 174.14 Billion KRW | -0.84% |
| 2022 Q1 | 39.51 Billion KRW | -12.15% |
| 2022 FY | 175.62 Billion KRW | 7.49% |
| 2022 Q4 | 46.56 Billion KRW | -0.76% |
| 2022 Q3 | 46.91 Billion KRW | 10.07% |
| 2022 Q2 | 42.62 Billion KRW | 7.87% |
| 2021 Q2 | 39.88 Billion KRW | 6.83% |
| 2021 Q1 | 37.32 Billion KRW | -3.36% |
| 2021 FY | 163.37 Billion KRW | 10.68% |
| 2021 Q4 | 44.98 Billion KRW | 9.21% |
| 2021 Q3 | 41.18 Billion KRW | 3.28% |
| 2020 Q2 | 39.85 Billion KRW | 22.21% |
| 2020 Q4 | 38.62 Billion KRW | 5.82% |
| 2020 Q3 | 36.5 Billion KRW | -8.42% |
| 2020 Q1 | 32.61 Billion KRW | -13.19% |
| 2020 FY | 147.6 Billion KRW | 0.92% |
| 2019 Q1 | 34.16 Billion KRW | -5.18% |
| 2019 FY | 146.26 Billion KRW | 6.32% |
| 2019 Q4 | 37.56 Billion KRW | 4.5% |
| 2019 Q3 | 35.95 Billion KRW | -6.79% |
| 2019 Q2 | 38.57 Billion KRW | 12.9% |
| 2018 Q1 | 32.83 Billion KRW | 15.13% |
| 2018 FY | 137.57 Billion KRW | 23.11% |
| 2018 Q2 | 33.91 Billion KRW | 3.27% |
| 2018 Q3 | 34.79 Billion KRW | 2.59% |
| 2018 Q4 | 36.03 Billion KRW | 3.56% |
| 2017 Q3 | 29.39 Billion KRW | 6.07% |
| 2017 FY | 111.74 Billion KRW | 11.46% |
| 2017 Q1 | 26.1 Billion KRW | -2.58% |
| 2017 Q2 | 27.71 Billion KRW | 6.15% |
| 2017 Q4 | 28.52 Billion KRW | -2.97% |
| 2016 Q3 | 25.28 Billion KRW | 0.21% |
| 2016 Q4 | 26.8 Billion KRW | 6.0% |
| 2016 Q1 | 22.93 Billion KRW | 0.0% |
| 2016 Q2 | 25.23 Billion KRW | 10.01% |
| 2016 FY | 100.25 Billion KRW | 46.79% |
| 2015 Q3 | 23.16 Billion KRW | 6.82% |
| 2015 Q1 | 21.52 Billion KRW | -5.09% |
| 2015 FY | 68.29 Billion KRW | -21.5% |
| 2015 Q2 | 21.68 Billion KRW | 0.73% |
| 2014 Q2 | 19.99 Billion KRW | 38.85% |
| 2014 Q1 | 14.4 Billion KRW | 1.79% |
| 2014 FY | 87 Billion KRW | 55.57% |
| 2014 Q4 | 22.68 Billion KRW | -0.54% |
| 2014 Q3 | 22.8 Billion KRW | 14.05% |
| 2013 FY | 55.92 Billion KRW | 4.34% |
| 2013 Q1 | 14.45 Billion KRW | 8.35% |
| 2013 Q2 | 12.88 Billion KRW | -10.9% |
| 2013 Q3 | 14.5 Billion KRW | 12.58% |
| 2013 Q4 | 14.14 Billion KRW | -2.44% |
| 2012 Q1 | 14.22 Billion KRW | 10.46% |
| 2012 Q2 | 12.86 Billion KRW | -9.54% |
| 2012 Q3 | 12.76 Billion KRW | -0.82% |
| 2012 FY | 53.6 Billion KRW | -0.82% |
| 2012 Q4 | 13.34 Billion KRW | 4.55% |
| 2011 Q2 | 13.17 Billion KRW | -0.98% |
| 2011 Q1 | 13.3 Billion KRW | 9.6% |
| 2011 FY | 54.04 Billion KRW | 2.8% |
| 2011 Q4 | 12.87 Billion KRW | 1.82% |
| 2011 Q3 | 12.64 Billion KRW | -3.98% |
| 2010 Q3 | 12.69 Billion KRW | -12.05% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 52.57 Billion KRW | 0.48% |
| 2010 Q2 | 14.43 Billion KRW | 0.0% |
| 2010 Q4 | 12.13 Billion KRW | -4.43% |
| 2009 Q1 | 11.55 Billion KRW | -2.63% |
| 2009 FY | 52.32 Billion KRW | 6.08% |
| 2009 Q4 | 11.89 Billion KRW | 6.92% |
| 2009 Q3 | 11.12 Billion KRW | -11.37% |
| 2009 Q2 | 12.54 Billion KRW | 8.63% |
| 2008 Q4 | 11.86 Billion KRW | -2.21% |
| 2008 FY | 49.32 Billion KRW | 6.05% |
| 2008 Q3 | 12.13 Billion KRW | -11.93% |
| 2008 Q2 | 13.77 Billion KRW | 29.01% |
| 2008 Q1 | 10.67 Billion KRW | -9.42% |
| 2007 Q2 | 12.55 Billion KRW | 0.0% |
| 2007 Q4 | 11.78 Billion KRW | 2.62% |
| 2007 FY | 46.5 Billion KRW | -1.21% |
| 2007 Q3 | 11.48 Billion KRW | -8.5% |
| 2006 FY | 47.08 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -268.538% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 41.559% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 37.455% |
| HANDOK Inc. | 153.76 Billion KRW | -13.254% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -151.61% |
| Yuhan Corporation | 489.94 Billion KRW | 64.456% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 43.266% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -316.728% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 71.496% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -141.929% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -334.794% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -86.153% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -51.797% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -268.538% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -310.034% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -132.046% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -196.958% |
| JW Holdings Corporation | 301.25 Billion KRW | 42.193% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 33.265% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 57.385% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 27.107% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -36.406% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -154.935% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -164.859% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 0.445% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -268.538% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 30.095% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 68.926% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 27.107% |
| Yuhan Corporation | 489.94 Billion KRW | 64.456% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 10.077% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -150.687% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -210.802% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 27.107% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -37.784% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -47.316% |
| CKD Bio Corp. | 25.19 Billion KRW | -591.182% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 21.554% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -5.472% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -162.203% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -36.406% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 50.345% |
| Boryung Corporation | 285.16 Billion KRW | 38.93% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -98.931% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 0.0% |
| JW Lifescience Corporation | 20.26 Billion KRW | -759.502% |